Pleurodesis

Pleurodesis is generally considered a minor to moderate procedure, not a major surgery, though the level of invasiveness depends on the type used and the person’s overall health. It is usually done to prevent fluid from building up around the lungs and to ease breathing, rather than to directly treat mesothelioma. Reported risks include pain, fever, infection, shortness of breath, bleeding, and, rarely, more serious complications such as acute respiratory distress syndrome or heart problems.

Life expectancy after pleurodesis varies widely because it depends on the underlying cancer, its stage, overall health, and other treatments such as chemotherapy or immunotherapy. For people with pleural mesothelioma who receive pleurodesis alone, published studies report a median survival of about 11 to 14 months, with 1‑year survival rates ranging from 18% to 57% and 2‑year survival rates from 10% to 13%. In broader groups of people with malignant pleural effusion from different cancers, median survival after talc pleurodesis typically ranges from about 8 to 11 months, compared with roughly 3 to 6 months for similar people without this procedure. Several studies also report that people who achieve a successful pleurodesis (no fluid coming back) often live a few months longer than those with recurrent effusions. However, researchers consistently note that these are averages from past cohorts and may not predict an individual person’s outcome.

Hospital stays after pleurodesis are usually short, often ranging from about 1 to 5 days, depending on the approach and how quickly the lung fully re-expands. Many centers report a “few days” in the hospital, with some describing typical stays of 2 to 3 days and others averaging 3 to 5 days. Studies of video-assisted thoracoscopic surgery (VATS) pleurodesis link length of stay closely to how long the chest drain needs to remain in place, often about 2 to 4 days when there are no complications. Once the chest tube is removed, pain is controlled, and imaging shows good lung expansion, people with mesothelioma or other conditions treated with pleurodesis are usually discharged the next day.

Yes. Pleurodesis is generally used as a palliative procedure for people with mesothelioma and other cancers that cause recurrent pleural effusions, because it aims to relieve shortness of breath and reduce fluid buildup rather than treat the underlying cancer. Studies and reviews describe it as a way to provide symptom control, with some reports showing symptom improvement in about 74% of people and lasting fluid control in many who respond. It is often discussed alongside other palliative options such as tunneled pleural catheters and repeated thoracentesis.